Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). (Q47579611)

From Wikidata

Jump to navigation Jump to search

scientific article published on 20 June 2014

Language	Label	Description	Also known as
English	Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).	scientific article published on 20 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT). (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

type 2 diabetes

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Helena M de Wit

1

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Gerald M M Vervoort

2

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Henry J Jansen

3

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Wim J C de Grauw

4

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Bastiaan E de Galan

5

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Cees J Tack

6

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

publication date

20 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

57

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

9

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

1812-1819

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

Timely initiation of basal insulin

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Contribution of change in glycosylated haemoglobin to insulin-associated weight gain: results of a longitudinal study in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

'Glucose control-related' and 'non-glucose control-related' effects of insulin on weight gain in newly insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Glucagon-like peptide-1, glucose homeostasis and diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Exenatide therapy in insulin-treated type 2 diabetes and obesity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Assessment of diabetes-related distress

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

An Inventory for Measuring Depression

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

American College of Sports Medicine Position Stand. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

1 reference

https://api.crossref.org/works/10.1007%2FS00125-014-3302-0

21 January 2018

Evaluation of a portable device to measure daily energy expenditure in free-living adults.

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON)

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of liraglutide added to U-500 insulin in patients with type 2 diabetes and high insulin requirements

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and efficacy of exenatide in combination with insulin in patients with type 2 diabetes mellitus

1 reference

https://pubmed.ncbi.nlm.nih.gov/24947583

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00125-014-3302-0

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 February 2018

http://europepmc.org/abstract/MED/24947583

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47579611&oldid=2208646286"